We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

41 hedge funds and large institutions have $3.05M invested in PDS Biotechnology in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

6.45% less ownership

Funds ownership: 16.09% → 9.64% (-6.5%)

7% less funds holding

Funds holding: 44 → 41 (-3)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

50% less capital invested

Capital invested by funds: $6.07M → $3.05M (-$3.01M)

Holders
41
Holders Change
-3
Holders Change %
-6.82%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
11
Reduced
9
Closed
9
Calls
$200K
Puts
–
Net Calls
+$200K
Net Calls Change
+$200K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$105K
2
Wells Fargo
Wells Fargo
California
+$79.1K
3
NMC
Nine Masts Capital
Hong Kong
+$50.8K
4
William Blair & Company
William Blair & Company
Illinois
+$37.6K
5
Renaissance Technologies
Renaissance Technologies
New York
+$33.2K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$2M
2
Squarepoint
Squarepoint
New York
-$148K
3
UBS Group
UBS Group
Switzerland
-$147K
4
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$79.7K
5
Northern Trust
Northern Trust
Illinois
-$26.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
UCFA
26
United Capital Financial Advisors
Texas
$7.26K +$9.03K +12,000 New
Raymond James Financial
27
Raymond James Financial
Florida
$6.19K -$2.63K -3,500 -25%
DC
28
Davenport & Co
Virginia
$6.05K – – –
GD
29
Grandfield & Dodd
New York
$6.05K – – –
Morgan Stanley
30
Morgan Stanley
New York
$2.37K -$752 -1,000 -20%
Group One Trading
31
Group One Trading
Illinois
$2.16K -$267 -355 -9%
CFD
32
Creative Financial Designs
Indiana
$1.81K – – –
Jones Financial Companies
33
Jones Financial Companies
Missouri
$1.08K – – –
TC
34
Truvestments Capital
Florida
$396 – – –
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$392 – – –
BWA
36
Basecamp Wealth Advisors
Washington
$228 – – –
Simplex Trading
37
Simplex Trading
Illinois
$163 -$14.2K -18,835 -99%
SS
38
SBI Securities
Japan
$71 +$7 +9 +8%
JP Morgan Chase
39
JP Morgan Chase
New York
$10 – – –
BIAS
40
Beacon Investment Advisory Services
New Jersey
$4 +$4 +5 New
Squarepoint
41
Squarepoint
New York
– -$148K -192,556 Closed
VF
42
Virtu Financial
New York
– -$25K -32,099 Closed
SG
43
StoneX Group
New York
– -$12.3K -16,000 Closed
First Manhattan
44
First Manhattan
New York
– -$11.5K -15,000 Closed
GSC
45
Ground Swell Capital
South Carolina
– -$11.3K -14,703 Closed
Citigroup
46
Citigroup
New York
– -$7.23K -9,393 Closed
TRCT
47
Tower Research Capital (TRC)
New York
– -$1.71K -2,220 Closed
Bank of America
48
Bank of America
North Carolina
– -$791 -1,028 Closed
Osaic Holdings
49
Osaic Holdings
Arizona
– -$13 -17 Closed
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
– +$8 +10 +15%
1
2

PDSB Hedge Fund Activity: Q1 2026 in Review

41 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2026, worth a combined $3.05M — down 50% from $6.07M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of PDSB and 7 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 11 added.

The largest buyer was Geode Capital Management, adding an estimated $105K. The largest seller was Armistice Capital, cutting an estimated $2M.

  • 41 institutional investors held PDS Biotechnology (PDSB) as of Q1 2026, down from 44 in Q4 2025.
  • Funds reported $3.05M of PDS Biotechnology stock for Q1 2026, down 50% quarter-over-quarter.
  • 7 funds opened new PDS Biotechnology positions in Q1 2026 and 9 closed out, a net change of -2 holders.
  • The largest PDS Biotechnology buyer in Q1 2026 was Geode Capital Management, an estimated $105K added.
  • The largest PDS Biotechnology seller in Q1 2026 was Armistice Capital, an estimated $2M sold.

Based on aggregated 13F filings for Q1 2026.